Literature DB >> 11136757

Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates.

M Heep1, B Brandstätter, U Rieger, N Lehn, E Richter, S Rüsch-Gerdes, S Niemann.   

Abstract

The prevalence of recently described mutation V176F, located in the beginning of the rpoB gene and associated with rifampin resistance and the wild-type cluster I sequence, was determined by analyzing the distribution of rpoB mutations among 80 rifampin (RIF)-resistant Mycobacterium tuberculosis strains isolated in Germany during 1997. The most frequent rpoB mutations were changes in codon 456 (52 isolates, 65%), followed by changes in codon 441 (13 isolates, 16%) and codon 451 (11 isolates, 14%). The V176F mutation was detected in one isolate of the study population and in 5 of 18 RIF-resistant strains with no cluster I mutation from six previously published studies. In three isolates, a mixture of resistant and susceptible subpopulations (heteroresistance) prohibited the detection of rpoB mutations in the initial analysis; however, in these isolates, cluster I mutations could be verified after a passage on RIF-containing medium. IS6110 DNA fingerprinting of 76 strains revealed eight clusters comprising 27 strains with identical restriction fragment length polymorphism patterns that mainly also show identical rpoB mutations and identical or similar drug resistance patterns. In conclusion, our results indicate that the V176F mutation should be included in molecular tests for prediction of RIF resistance in M. tuberculosis. We further demonstrated that heteroresistance caused by a mixture of mycobacterial subpopulations with different susceptibilities to RIF may influence the sensitivity of molecular tests for detection of resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11136757      PMCID: PMC87688          DOI: 10.1128/JCM.39.1.107-110.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis.

Authors:  M Heep; U Rieger; D Beck; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 2.  Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

Authors:  S Ramaswamy; J M Musser
Journal:  Tuber Lung Dis       Date:  1998

3.  Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan.

Authors:  H Ohno; H Koga; S Kohno; T Tashiro; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

4.  Qualitative and quantitative drug-susceptibility tests in mycobacteriology.

Authors:  L Heifets
Journal:  Am Rev Respir Dis       Date:  1988-05

5.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

6.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

Authors:  A Telenti; P Imboden; F Marchesi; D Lowrie; S Cole; M J Colston; L Matter; K Schopfer; T Bodmer
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

7.  Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas.

Authors:  V Kapur; L L Li; S Iordanescu; M R Hamrick; A Wanger; B N Kreiswirth; J M Musser
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

8.  Characterization of rifampin-resistance in pathogenic mycobacteria.

Authors:  D L Williams; C Waguespack; K Eisenach; J T Crawford; F Portaels; M Salfinger; C M Nolan; C Abe; V Sticht-Groh; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  Prospective evaluation of the utility of molecular techniques for diagnosing nosocomial transmission of multidrug-resistant tuberculosis.

Authors:  F R Cockerill; D E Williams; K D Eisenach; B C Kline; L K Miller; L Stockman; J Voyles; G M Caron; S K Bundy; G D Roberts; W R Wilson; A C Whelen; J M Hunt; D H Persing
Journal:  Mayo Clin Proc       Date:  1996-03       Impact factor: 7.616

10.  Surveillance of tuberculosis in Europe. Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting on tuberculosis cases.

Authors:  H L Rieder; J M Watson; M C Raviglione; M Forssbohm; G B Migliori; V Schwoebel; A G Leitch; J P Zellweger
Journal:  Eur Respir J       Date:  1996-05       Impact factor: 16.671

View more
  87 in total

1.  Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay.

Authors:  Z Bártfai; A Somoskövi; C Ködmön; N Szabó; E Puskás; L Kosztolányi; E Faragó; J Mester; L M Parsons; M Salfinger
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

2.  Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay.

Authors:  Cengiz Cavusoglu; Suleyha Hilmioglu; Sevinc Guneri; Altinay Bilgic
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

3.  Rapid identification of mycobacteria and drug-resistant Mycobacterium tuberculosis by use of a single multiplex PCR and DNA sequencing.

Authors:  Ailyn C Pérez-Osorio; David S Boyle; Zachary K Ingham; Alla Ostash; Romesh K Gautom; Craig Colombel; Yolanda Houze; Brandon T Leader
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

4.  The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.

Authors:  Yaoju Tan; Zuqiong Hu; Yanlin Zhao; Xingshan Cai; Chunming Luo; Cairong Zou; Xin Liu
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

5.  Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China.

Authors:  Jun Yue; Wei Shi; Jingping Xie; Yao Li; Erliang Zeng; Honghai Wang
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

6.  Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs.

Authors:  Zohar B Weinstein; Muhammad H Zaman
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

7.  Disequilibrium in distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-Beijing strains isolated from patients in Germany.

Authors:  Doris Hillemann; Tanja Kubica; Sabine Rüsch-Gerdes; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

8.  Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam.

Authors:  M Caws; Phan Minh Duy; Dau Quang Tho; Nguyen Thi Ngoc Lan; Dai Viet Hoa; Jeremy Farrar
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

9.  Evaluation of the TB-Biochip oligonucleotide microarray system for rapid detection of rifampin resistance in Mycobacterium tuberculosis.

Authors:  Janice C Caoili; Angelina Mayorova; David Sikes; Laura Hickman; Bonnie B Plikaytis; Thomas M Shinnick
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

10.  Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy.

Authors:  Paolo Miotto; Federica Piana; Valeria Penati; Filippo Canducci; Giovanni Battista Migliori; Daniela Maria Cirillo
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.